Revolution Medicines, Inc. (RVMD) Stock Price & Analysis
Revolution Medicines, Inc. (RVMD) rose 0.71% to USD 149.55 as of June 9, 2026 at 23:47 UTC, according to Nexqual real-time market data.
RVMD last closed at USD 148.49; the session ranged USD 146.5–151.09 on volume of 2,764,880 shares. Market capitalization is $31.79B, with a 52-week range of USD 34–166.5 (NMS). Source: Nexqual, June 9, 2026 at 23:47 UTC.
Key Statistics (as of June 9, 2026 at 23:47 UTC)
| Price | USD 149.55 |
|---|---|
| Change | ▲ 0.71% (up) |
| Previous Close | USD 148.49 |
| Open | USD 150.23 |
| Day Range | USD 146.5 – 151.09 |
| 52-Week Range | USD 34 – 166.5 |
| Volume | 2,764,880 shares |
| Market Cap | $31.79B |
| Exchange | NMS |
Technical Analysis (RVMD)
Nexqual's technical model rates RVMD "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 23:47 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 49.75 (neutral) |
| vs SMA50 | Above (USD 138.33) |
| MACD | 3.57 (positive) |
Analyst Ratings (RVMD)
Wall Street analysts rate RVMD "Strong Buy" based on 21 analysts, with a mean price target of USD 186.33 (range USD 151–263), per Nexqual as of June 9, 2026 at 23:47 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 21 |
| Mean Target | USD 186.33 |
| High Target | USD 263 |
| Low Target | USD 151 |
| Buy / Hold / Sell | 21 / 1 / 0 |
Earnings (RVMD)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -2.03 |
| Revenue Estimate | $17.11M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -2.29 vs est -1.84 ▼ miss |
| 2025-12-31 | USD -1.86 vs est -1.56 ▼ miss |
| 2025-09-30 | USD -1.61 vs est -1.41 ▼ miss |
| 2025-06-30 | USD -1.31 vs est -1.12 ▼ miss |
Source: Nexqual, June 9, 2026 at 23:47 UTC.
Financials & Fundamentals (RVMD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -76.67% |
| Debt / Equity | 29.15 |
| Current Ratio | 6.8 |
| Total Cash | $1.91B |
| Total Debt | $437.27M |
| Free Cash Flow | $-606.37M |
Source: Nexqual, June 9, 2026 at 23:47 UTC.
Financial Health Score (RVMD)
Nexqual rates Revolution Medicines, Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:47 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $1.91B cash vs $437M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$1.06B |
| Efficiency | Critical — ROE -77%, ROA -37.5% |
Ownership (RVMD)
| Insider Ownership | +1.90% |
|---|---|
| Institutional Ownership | +95.59% |
| Shares Outstanding | 212.60M |
| Float | 194.17M |
| Short % of Float | +5.50% |
Source: Nexqual, June 9, 2026 at 23:47 UTC.
Leadership (RVMD)
Revolution Medicines, Inc. is led by Mark A. Goldsmith (age 63), CEO, President & Chairman, per Nexqual as of June 9, 2026 at 23:47 UTC.
| CEO, President & Chairman | Mark A. Goldsmith (age 63) |
|---|---|
| Chief Financial Officer | Jack Anders (age 48) |
| Chief Operating Officer | Margaret A. Horn (age 62) |
| President of Research & Development | Stephen M. Kelsey FRC Path., FRCP (age 64) |
| Co-Founder & Chairman of Scientific Advisory Board | Martin D. Burke |
Major Backers & Investors (RVMD)
Notable institutional backers of Revolution Medicines, Inc. include Farallon Capital Management LLC, Janus Henderson Group PLC, Baker Bros. Advisors, LP, according to Nexqual as of June 9, 2026 at 23:47 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Farallon Capital Management LLC | 6.4% |
| Janus Henderson Group PLC | 4.59% |
| Baker Bros. Advisors, LP | 4.49% |
| FMR, LLC | 3.98% |
| Nextech Invest, Ltd. | 3.58% |
| Paradigm Biocapital Advisors LP | 3.13% |
| Wellington Management | 2.84% |
| Fidelity | 1.68% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.52% |
| BlackRock | 5.87% |
Source: Nexqual, June 9, 2026 at 23:47 UTC.
From Revolution Medicines, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
- The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
- Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | USD 76.91 | ▲ 3.75% |
| RLAY | Relay Therapeutics, Inc. | USD 14.09 | ▲ 4.22% |
| PCVX | Vaxcyte, Inc. | USD 46.88 | ▼ 1.01% |
| BBIO | BridgeBio Pharma, Inc. | USD 67.68 | ▲ 0.1% |
| LEGN | Legend Biotech Corporation | USD 33.49 | ▲ 2.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:47 UTC. This page is informational and not investment advice.